Agios Pharmaceuticals公司（AGIO）宣布，其药物Tebapivat在临床试验中取得了积极结果。数据显示，接受Tebapivat治疗的患者组中，达到主要终点的比例最高可达47.1%。相比之下，安慰剂对照组的这一比例则为33.3%。这一结果凸显了该试验性疗法的潜在疗效优势。
Agios Pharmaceuticals公司（AGIO）宣布，其药物Tebapivat在临床试验中取得了积极结果。数据显示，接受Tebapivat治疗的患者组中，达到主要终点的比例最高可达47.1%。相比之下，安慰剂对照组的这一比例则为33.3%。这一结果凸显了该试验性疗法的潜在疗效优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.